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cancer, and the general population, respectively (0 = worst; 52 =
least fatigue). Ten-year total per patient costs (drug, monitoring,
physician visits, adverse events) for managing GIST patients with
molecularly targeted treatment were estimated at £47,086–
£70,811 compared to £3674–£4230 with best supportive care.
CONCLUSIONS: Data suggest the incidence of GIST is similar
across countries; lower incidence in one study is likely explained
by differences in method of case ascertainment. Although
patients with GIST present with fatigue comparable to other
cancers, additional research is needed to comprehensively under-
stand its HRQL burden. The increased cost associated with new
therapies must be balanced against their expected beneﬁts.
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OBJECTIVES: To determine incidence and ﬁve years survival rate
of renal parenchyma tumours by TNM stage using cases recorded
in seven French departments cancer registries. To estimate overall
and with metastasis cancer prevalence, at the end of 2004, when
diagnosed over the period 2000–2004. METHODS: Identiﬁca-
tion of patients using the databases of seven cancer registries.
Data collected trough medical records and administrative data
(vital states). Assessment of raw global survival rate using Kaplan
Meier curves. Determination of global prevalence by summing
2000–2004 annual incident cases for which corresponding global
survival data have been applied. Same method for the estimation
of prevalence without metastases. Prevalence with metastases 
is global prevalence minus prevalence without metastases.
RESULTS: A total of 597 cases were identiﬁed and analized. 84%
of cases consisted of clear cell adenocarcinoma. Thus, the stan-
dardised levels of incidence (worldwide reference population) are
estimated to be 9.91 per 100,000 men and 3.75 per 100,000
women. Stages I, II, III and IV had speciﬁc incidences respectively
of 4.7, 1.1, 1.9 and 2.7 per 100,000 subjects. The 5 years sur-
vival rate in men and women was respectively 55% (CI95: 50–60)
and 65% (CI95: 58–71). Survival decreased with age and with
stage extension. The national number of cases is estimated to be
6,482 cases. Accordingly, the estimated partial global prevalence
is 29,300 cases, including 4,860 with metastasis (16.6%), this
rate increases with age: from 11% for patients aged less than 60
years to 29% for patients aged 80 years and over. CONCLU-
SIONS: This study is the ﬁrst one to give an estimation of spe-
ciﬁc parenchyma cancer by stage incidence, on a population base.
On this base, this study also provides prevalence estimations for
evolutive cancers.
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OBJECTIVE: Renal cell carcinoma has an asymptomatic course
and 25–30% of patients present with metastatic disease at time
of diagnosis. Molecularly targeted therapies (MTTs) represent a
breakthrough in treatment of mRCC, prolonging life, reducing
toxicity and the negative impact of treatment on health-related
quality of life (HRQOL), and offering viable therapeutic options
to a broader patient population relative to immunotherapy. The
objective of this study was to explore the burden of mRCC and
the potential clinical, economic and humanistic value of MTTs.
METHODS: PubMed, scientiﬁc meeting and online databases
were searched for articles relating to the epidemiologic, human-
istic and economic burden of mRCC. Thirty-ﬁve articles 
were selected. Epidemiology and economic statistics for mRCC
were estimated from international registries and published data
sources. RESULTS: Approximately 1500–8600 new mRCC
cases occur annually in major European and North American
countries, and Japan. Standard immunotherapy is largely inef-
fective (less than 10% response rates; no beneﬁt in most patients,
especially the elderly) despite a high annual cost of treatment
(e.g., $15,500–$82,000 across countries). In the absence of effec-
tive treatment, mRCC is rapidly fatal with 13% or fewer patients
surviving and a median survival of less than 1 year. Two-year
costs of care for mRCC have been estimated at $35,735/year
(US$). HRQOL of mRCC patients is comparable to congestive
heart failure, diabetes and other cancer patients and may be
further diminished by systemic immunotherapy. Recent studies
show that MTTs produce marked improvements in response
rates/survival, and tolerability without negative impact on
HRQL. CONCLUSIONS: The need for MTTs for mRCC is
characterized by the lack of effective treatment for the vast
majority of patients, high mortality, and considerable humanis-
tic and economic burden. Meaningful improvements in effec-
tiveness and tolerability in this patient population suggest that
MTTs offer economic and humanistic value in the treatment of
mRCC.
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ESP are standard treatment options for CIA. In this setting, both
Epoetin (EPO) alfa and EPObeta are administered three
times/week (TIW) or once/week (QW), while darbepoetin alfa
(DA) is the only ESP approved to be administered as once every
three weeks (Q3W). For ESP administered TIW or QW the SPCs
states to double the dose if hemoglobine increases <1 g/dL after
4 weeks. Doubling the dose is not needed with starting dose DA
500 μg Q3W. These administration differences might result in
different treatment costs for each agent. OBJECTIVE: Estimate
BI (mean cost/patient) of administering the different ESP in the
treatment of CIA in Spain. METHODS: The following variables
were considered in the economic model: ESP ex-manufacturer
price in Spain, administration pattern, weeks of treatment (12
weeks), weeks of evaluation before increments of dose (4 weeks),
dose increases, and overall cost of one administration (€59.72).
In addition, a two-way sensitivity analysis was performed to test
the robustness of the results, considering the following variables:
1) administration cost from a minimum of 0 to +25%, and 2)
the lowest and highest percentage of patients needing to increase
dose for EPOalfa and EPObeta from six studies found in the lit-
erature where this data was reported. RESULTS: In the base case
scenario, assuming an incidence of doubling the dose with both
EPOalfa and EPObeta of 29.60%, which was the mean value
